| Ticker: | JAGX |
| Current Price: | $4.18 |
| % Daily Change: | 0.48% |
| Volume (1,000s): | 1,250.93 |
| Average Volume (1,000s): | 106.71 |
| Market Cap (M): | $1.81 |
| 1/2/2024 Price: | $0.95 |
| Change Since Inception: | 340.46% |
Jaguar Health, Inc.
200 Pine Street
Suite 400
San Francisco, CA 94104
United States
Jaguar Health (NASDAQ: JAGX) (“Jaguar”) is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Napo Pharmaceuticals, a Jaguar company, focuses on developing and commercializing proprietary human pharmaceuticals from plants harvested responsibly from rainforest areas. Jaguar is the majority shareholder of Napo Therapeutics S.p.A., a corporation established by Jaguar in Italy in 2021 that focuses on expanding crofelemer access in Europe. Jaguar Animal Health is a tradename of Jaguar Health.
The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs.